Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
IDIA(IDIA) Allschwil, Switzerland – September 10, 2025
Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at World Sleep 2025, delivering on its ongoing commitment to further the science of sleep and insomnia.
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension
IDIA(IDIA) Allschwil, Switzerland & Radnor, Philadelphia – September 5, 2025
Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple medications for difficult-to-control hypertension face increasing challenges with care coordination, evaluation of underlying causes, and worsening outcomes. The initiative, led by Dr. Vivek Bhalla of the Stanford University School of Medicine and Dr. Sreekanth Vemulapalli of Duke University School of Medicine, is expected to generate real-world evidence, standardize clinical decision-making and deliver scalable tools that leverage AI technology to help identify patients with difficult-to-control hypertension who may benefit from innovative therapies that utilize new pathways, including Idorsia's once-daily TRYVIO™ (aprocitentan), the first syst
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
IDIA(IDIA) Allschwil, Switzerland – September 1, 2025
Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sleep 2025, a global scientific congress bringing the best of sleep medicine and research, in Singapore from September 5-10, 2025.
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
IDIAAllschwil, Switzerland – August 28, 2025
Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for difficult-to-control hypertension. In addition, the company will host a live investor Q&A on September 8, 2025, following the American Heart Association's (AHA) Hypertension Scientific Sessions.
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension
IDIAAllschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025
Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic hypertension, published by the American College of Cardiology (ACC) and the American Heart Association (AHA) Joint Committee. The updated recommendations now list TRYVIO as a therapy that may be added for adults with difficult-to-control hypertension, including resistant hypertension. TRYVIO is the first systemic hypertension treatment to target a new pathway in over 30 years and the only new medicine to be included in the updated guidelines.
TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”
IDIAAllschwil, Switzerland – August 12, 2025
Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nominated TRYVIO™ (aprocitentan) in the category of “Best Pharmaceutical Product” in the 2025 Prix Galien USA awards. The winner will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025.
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
IDIAAd hoc announcement pursuant to Art. 53 LR